Drug Database
LE

levetiracetam (Spritam)

✓ Approved

Aprecia Pharmaceuticals, LLC. · SV2A · 小分子

什么是 levetiracetam?

levetiracetam 是一种小分子,由Aprecia Pharmaceuticals, LLC.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)、Sublingual (SL)/Oral Transmucosal。

药物档案

商品名Spritam
公司Aprecia Pharmaceuticals, LLC.
药物类别小分子
分子靶点SV2A
给药途径Oral (PO), Sublingual (SL)/Oral Transmucosal
状态Approved

作用机制

分子靶点

levetiracetam 作用于 1 个分子靶点:

SV2Asynaptic vesicle glycoprotein 2A (SLC22B1, DEE113)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

levetiracetam 针对 3 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersGeneralised tonic-clonic seizure✓ Approved
Nervous system disordersMyoclonic epilepsy✓ Approved
Nervous system disordersPartial seizures✓ Approved

相关研究文献

PubMedEpilepsia open2026-11-15

Real-world antiseizure medication prescribing and treatment pathways in a pediatric health care system.

Abend Jack E JE, Gonzalez Alex K AK, Kaufman Michael C MC, Fitzgerald Mark P MP

To characterize antiseizure medication (ASM) selection, subsequent ASM prescribing, and treatment pathways among patients with epilepsy receiving care within a pediatric health care system. We conducted a retrospective electronic health record study over 17 years. Each unique ASM was counted once per patient, and ASMs were ordered by the date of their first observed prescription. For each observed ASM, we determined whether a subsequent unique ASM was prescribed during available follow-up. Prescription of a third unique ASM was used as a proxy for potential drug-resistant epilepsy. Among 20 009 patients, 27 ASMs and 3507 treatment pathways were identified. The most common first-observed ASMs were levetiracetam (35.1%), oxcarbazepine (17.2%), and valproic acid (12.3%). From 2010 to 2026, the proportion of first-observed prescriptions for levetiracetam increased from 23.1% to 41.5%. The proportion of all distinct ASMs first recorded for individual patients that were newer-generation ASMs increased from 0% in 2010 to 9.1% in 2026. The proportion of patients without a subsequent ASM ranged from 16.2% to 69.6% across commonly prescribed first-observed ASMs. Overall, 55.6% of patients had one unique ASM recorded, 22.4% had two, and 22.0% had at least three, thereby meeting the study's prescription-based proxy for potential drug-resistant epilepsy. Beyond the most common single- and two-ASM pathways, each remaining pathway accounted for less than 1% of the cohort. Prescribing remained concentrated among established ASMs, although their relative use changed substantially. The proportion of patients without a subsequent ASM varied widely across medications, and treatment pathways beyond first-observed therapy were highly heterogeneous. These findings characterize real-world treatment patterns and identify a need for comparative effectiveness studies of ASM sequencing. We examined antiseizure medication prescribing over 17 years among more than 20 000 patients with epilepsy receiving care in a pediatric health care system. More than half had only one medication recorded, whereas 22% had at least three medications; however, the available records could not determine whether these medications failed to control seizures. Levetiracetam became more commonly prescribed, newer medications remained a small proportion of overall use, and medication sequences varied widely after the first observed treatment. These findings highlight the need for better evidence to guide medication selection after initial treatment.

PMID 43033003
阅读全文 →
PubMedBone marrow transplantation2026-11-14

Optimal levetiracetam dosage regimen for preventing seizures related to immune effector cell-associated neurotoxicity syndrome.

Sugimoto Yuri Y, Tsuchiya Yuichi Y, Wada Yudai Y, Yamamoto Nanae N et al.

PMID 43026258
阅读全文 →
PubMedInternational journal of molecular sciences2026-11-14

Genetic Variations in Neuroinflammatory Chemokine Receptor Genes in Patients with Epilepsy: An Exploratory Study.

Pekkoc-Uyanik Kubra Cigdem KC, Agay Erhan Rasit ER, Uzun Hafize H

Epilepsy is a common neurological disorder in which genetic and neuroinflammatory mechanisms may contribute to differences in seizure control. Chemokine receptor signaling plays an important role in inflammatory processes, and genetic variations in neuroinflammatory chemokine receptor genes may potentially influence the prognosis of epilepsy. This study aimed to investigate genetic variations in the neuroinflammatory chemokine receptor genes CCR5 and CXCR4 in patients with epilepsy and to explore their potential association with seizure control during treatment. Targeted next-generation sequencing (tNGS) was performed to investigate genetic variations in the CCR5 and CXCR4 genes using genomic DNA obtained from 22 patients with epilepsy receiving antiseizure medication (ASM) treatment with levetiracetam and/or valproic acid. Patients were classified into two groups according to seizure frequency to evaluate the association between genetic variation and clinical prognosis. A total of seven genetic variants were identified in the CCR5 and CXCR4 genes, including three variants in CCR5 and four variants in CXCR4. However, sufficient genotype variation for group-wise comparisons was available only for CCR5 rs1799988 and rs1800023. No significant differences were observed in the genotype or allele distributions of the CCR5 and CXCR4 gene variants between the responsive and persistent groups. The two CCR5 variants, rs1799988 and rs1800023, showed strong linkage disequilibrium (D' = 1.000, r2 = 0.913) and were included in a single haplotype block. None of the identified CCR5 haplotypes was significantly associated with seizure control. In this preliminary cohort, no statistically significant associations were detected between the analyzed genetic variations and seizure control during treatment; however, the limited sample size may have reduced the statistical power to detect potential associations. Strong linkage disequilibrium was observed between rs1799988 and rs1800023 (D' = 1.000, r2 = 0.913), consistent with previously reported patterns. Given the small sample size and the limited number of informative variants, these findings should be interpreted as preliminary and hypothesis-generating rather than as evidence for or against a genetic contribution to seizure control. Larger, independent cohorts are needed to assess the potential clinical relevance of CCR5 and CXCR4 variation in epilepsy.

PMID 43027722
阅读全文 →
PubMedMedicine2026-11-13

Association between antiseizure medications and thrombocytopenia: A retrospective pharmacovigilance study using the US FAERS, Japanese JADER, and Canadian CVARD databases.

Huang Jie J, Jin Bao-Fen BF, Mai Zhi-Kai ZK, Zhao Pei-Jin PJ et al.

Thrombocytopenia is a clinically important hematological adverse event associated with several antiseizure medications (ASMs), but comparative real-world evidence across individual drugs and pharmacovigilance databases remains limited. We conducted a retrospective pharmacovigilance study using the US Food and Drug Administration Adverse Event Reporting System (FAERS) from Q1 2004 to Q2 2025, with supportive cross-database comparisons using the Japanese adverse drug event report database and the Canada vigilance adverse reaction database from January 2004 to June 2025. Thrombocytopenia events were identified using the narrow Standardized Medical Dictionary for Regulatory Activities Query "hematopoietic thrombocytopenia." Disproportionality was assessed using the reporting odds ratio and Bayesian confidence propagation neural network, and subgroup, time-to-onset, and univariable logistic regression analyses of reported fatal outcomes were also performed. In FAERS, 4835 reports with ASMs designated as primary suspect drugs were identified, corresponding to 4900 thrombocytopenia events. Positive disproportionality signals were detected for valproic acid, levetiracetam, and carbamazepine. Adults aged ≥65 years had the shortest median time to onset (14 days), and reports with serious outcomes had an earlier onset than reports without a recorded serious outcome (13 vs 29 days). Based on the reporting odds ratio criterion, valproic acid showed positive reporting signals in all 3 databases, whereas levetiracetam showed signals in FAERS and Canada Vigilance Adverse Reaction Database and carbamazepine in FAERS and Japanese adverse drug event report. Overall, this study identified drug-specific thrombocytopenia reporting signals and earlier onset patterns among older adults and reports with serious outcomes. These hypothesis-generating findings warrant further epidemiological evaluation and may inform studies of risk-adapted monitoring; they do not establish incidence, comparative safety, or causality.

PMID 43024290
阅读全文 →
PubMedAnaesthesia and intensive care2026-11-12

A case of massive gamma-hydroxybutyrate overdose mimicking brain death.

Chua Verene V, Balakumaran Nanthini N, Neal John J, Azad Raman R et al.

A 36-year-old female was brought into hospital following a massive overdose of 100 ml of gamma-hydroxybutyrate. Unlike prior case reports where ethanol was a co-ingestant with gamma-hydroxybutyrate or its precursor, gamma-hydroxybutyrate was believed to have been the only substance ingested in this case. The patient developed a severe and persistent high anion gap metabolic acidosis and required continuous renal replacement therapy. The patient developed fixed and dilated pupils early on in her clinical course and was found to have a transient loss of most brainstem reflexes on clinical examination, thus mimicking brain death. She also developed generalised tonic-clonic seizures and received midazolam and levetiracetam for seizure control. She was successfully extubated after 5 days on mechanical ventilation and was discharged home on day 11 with no neurological deficits.

PMID 43016365
阅读全文 →
PubMedBMC neurology2026-11-11

Evaluation of factors affecting therapeutic levetiracetam drug levels in intensive care unit patients: a retrospective study.

Ayhan Yunus Emre YE, Küçük Rabia Sari RS, Ervatan Zekeriya Z, Bektay Muhammed Yunus MY

Levetiracetam (LEV) is a widely used anti-seizure medication (ASM) with linear pharmacokinetics and a wide therapeutic range. Although therapeutic drug monitoring (TDM) for LEV is not routinely recommended, critically ill patients in the intensive care unit (ICU) may experience altered pharmacokinetics. This study aimed to evaluate the factors influencing LEV serum levels in ICU patients and to identify predictors of therapeutic drug concentrations. This retrospective observational study included ICU patients aged ≥ 18 years who received LEV therapy and underwent TDM between January 2021 and July 2024 at a tertiary care hospital. LEV serum levels were categorized as subtherapeutic (< 12 mg/L), therapeutic (12-46 mg/L), or supratherapeutic (> 46 mg/L). Data on demographics, clinical parameters, renal function (estimated glomerular filtration rate [eGFR] calculated with the CKD-EPI 2009 equation and used as a surrogate for creatinine clearance), and concurrent ASM use were analyzed. Predictors of log-transformed LEV concentration were assessed using multiple linear regression. A total of 66 patients were included, with 59.1% achieving therapeutic LEV levels. Subtherapeutic and supratherapeutic levels were observed in 25.8% and 15.2% of patients, respectively. Advanced age and renal dysfunction (eGFR < 30 mL/min/1.73 m²) were significantly associated with supratherapeutic levels (p = 0.044 and p < 0.001, respectively). In multiple linear regression on log-transformed concentrations, renal dysfunction (+ 150%), in-hospital death, treatment rather than prophylactic indication, and daily LEV dose were independent predictors of serum LEV concentration (adjusted R² = 0.325, p < 0.001). LEV concentration did not discriminate seizure occurrence (area under the receiver operating characteristic curve 0.568, 95% CI 0.415-0.722). LEV concentrations showed substantial variability in ICU patients and were independently associated with renal function, LEV dose, indication, and discharge status. However, serum LEV concentration did not discriminate seizure occurrence. These findings support individualized interpretation of LEV TDM results, particularly at the extremes of renal function, but do not demonstrate that achieving the predefined reference range improves seizure control or clinical outcomes.

PMID 43009842
阅读全文 →

注册免费账户还可查看另外 6495 篇文献

免费注册查看全部文献 →

了解更多levetiracetam